← Back to Search

Angiotensin Converting Enzyme Inhibitor

Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients (SARTAN-AD Trial)

Phase 2
Waitlist Available
Led By Sandra Black, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 & 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing blood pressure medications to see if they can slow brain shrinkage in patients with mild to moderate Alzheimer's Disease. The goal is to find out if these medications can protect the brain and slow down the progression of the disease.

Eligible Conditions
  • Alzheimer's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 & 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 & 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety - Adverse Events
Safety - Blood pressure
Safety - Electrolytes
+2 more
Secondary study objectives
Cognitive and functional measures
Grey/White matter volume
Hippocampal volume
Other study objectives
Neuropsychiatric Measures
Quality of Life - Caregiver burden
Quality of Life - Health-related
+2 more

Side effects data

From 2016 Phase 4 trial • 33 Patients • NCT02079805
13%
Nasopharyngitis
6%
Abdominal pain lower
6%
Chest discomfort
6%
Bronchitis
6%
Influenza
6%
Diabetes mellitus
6%
Vaginal haemorrhage
6%
Cutaneous amyloidosis
6%
Back pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Telmisartan 40 mg
Azilsartan 20 mg

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TelmisartanExperimental Treatment1 Intervention
Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
Group II: PerindoprilActive Control1 Intervention
Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Telmisartan
1999
Completed Phase 4
~14550

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
680 Previous Clinical Trials
1,565,716 Total Patients Enrolled
Weston Brain InstituteOTHER
11 Previous Clinical Trials
823 Total Patients Enrolled
Alzheimer's Drug Discovery FoundationOTHER
21 Previous Clinical Trials
2,964 Total Patients Enrolled
Sandra Black, MDPrincipal InvestigatorSunnybrook Health Sciences Centre
5 Previous Clinical Trials
920 Total Patients Enrolled
Krista Lanctot, PhDPrincipal InvestigatorSunnybrook Research Institute
3 Previous Clinical Trials
104 Total Patients Enrolled

Media Library

Perindopril (Angiotensin Converting Enzyme Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02085265 — Phase 2
Perindopril (Angiotensin Converting Enzyme Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02085265 — Phase 2
Alzheimer's Disease Research Study Groups: Perindopril, Telmisartan
Alzheimer's Disease Clinical Trial 2023: Perindopril Highlights & Side Effects. Trial Name: NCT02085265 — Phase 2
~13 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top